Profile
HDAX Therapeutics, a biotechnology company pioneering a novel approach to target HDAC6 to address critical unmet medical needs in renal, cardiometabolic and select neurological diseases, starting with ADPKD. Its innovative 2-site binding mechanism has the potential to deliver best-in-class HDAC6-targeting therapeutics and tackles major limitations of first generation compounds. HDAX closed an oversubscribed $4M seed financing round in Q4 2024 to nominate a development candidate and advance its pipeline programs.
Event details
Date: January 12 - 14, 2026
Event contact
Patricia Cosgrove
Senior International Market Consultant
U.S.A. & Europe
Tel: +1 647-293-6306
Email: patricia.cosgrove@ontario.ca
Participants
21 in total
-
20/20 OptimEyes Technologies has developed a mucoadhesive drug delivery platform technology that allows for… -
BioBox is a data integration and decision-intelligence platform for drug discovery. It helps biopharma bring… -
Eurofins CDMO Alphora develops and… -
Fibra turns everyday underwear into a real-time reproductive health platform — capturing critical biomarker data… -
For over two decades, Toronto area-based GL CHEMTEC has been dedicated to delivering innovative… -
HDAX Therapeutics, a biotechnology company pioneering a novel approach to target… -
ImmunoBiochem is a pharma-partnered biotech developing novel bioconjugate therapeutics, such as… -
Iseehear Inc. is a leading provider of comprehensive IT solutions for… -
Kapoose Creek Bio is pioneering a new generation of therapeutics by fusing nature’s untapped chemistry with… -
Lumerate is launching a new software brand called BioBackers - the intelligence platform for life science… -
Medicenna is a clinical-stage immunotherapy company pioneering best- and/or first-in-class Superkines -… -
Noa Therapeutics has developed a proprietary NRF2-… -
Nucro-Technics is a GLP- and… -
Paradox Immunotherapeutics is a biotech addressing the global burden of protein misfolding diseases—devastating… -
Pattern Pharma’s patent-protected immunotherapeutic, PPI-100, mobilizes innate immunity by targeting… -
ProteinQure has built the best computational platform for designing peptides for extra-cellular targets. PQ… -
QurCan Therapeutics is advancing the next wave of genetic medicines for CNS… -
Rhythm Biotherapeutics develops first-in-class, heart-derived exosome therapeutics to prevent atrial fibrillation… -
Spiderwort is a platform biomaterials company developing a suite of cellulose-based scaffolds for use in a number… -
Tenomix’s mission is to develop novel technologies that target inefficiencies in the pathology workflow, optimize… -
Transpharmation is a contract research organisation led by scientists. Recognised by drug developers worldwide…